MapLight said the twice-daily dose met the primary endpoint of the schizophrenia trial, but the daily dose did not.
If Andembry reaches the paediatric HAE market, it would have to contend with the best-seller Takhzyro and new oral option Orladeyo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results